Tapentadol Modified Release
Indication
Pain in the non-palliative care setting
Brand:
Palexia SR
Nice TA:
Commissioning responsibility:
CCG (HRG included)
PbR excluded:
No
Background
Tapentadol MR is NOT recommended for use by the NHS in Lancashire and South Cumbria in the following settings:
• as a treatment option for intractable neuropathic pain in non-palliative care patients.
• as a treatment for nonspecific pain
There is insufficient evidence to consistently demonstrate improved efficacy in the above settings when compared to opioid drugs and there is a lack of significant evidence to demonstrate efficacy in patients inadequately controlled on opioid drugs.
A review of use in patients with intractable neuropathic pain in palliative care is currently being drafted.
*FOR WEST LANCASHIRE CCG ONLY* Tapentadol is commissioned in accordance with the Pan Mersey formulary
Recommendation
LSCMMG Recommendation:
Black
Reason for decision:
Not recommended for prescribing on the NHS in Lancashire & South Cumbria